Sanara Medtech Inc. (SMTI) Stock Price & Analysis
Sanara Medtech Inc. (SMTI) rose 0.24% to USD 25.56 as of July 25, 2026 at 17:39 UTC, according to Nexqual real-time market data.
SMTI last closed at USD 25.5; the session ranged USD 25.32–25.86 on volume of 50,212 shares. Market capitalization is $234.23M, with a 52-week range of USD 16.05–35.95 (NCM). Source: Nexqual, July 25, 2026 at 17:39 UTC.
Key Statistics (as of July 25, 2026 at 17:39 UTC)
| Price | USD 25.56 |
|---|---|
| Change | ▲ 0.24% (up) |
| Previous Close | USD 25.5 |
| Open | USD 25.5 |
| Day Range | USD 25.32 – 25.86 |
| 52-Week Range | USD 16.05 – 35.95 |
| Volume | 50,212 shares |
| Market Cap | $234.23M |
| Exchange | NCM |
Technical Analysis (SMTI)
Nexqual's technical model rates SMTI "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 17:39 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 59.28 (neutral) |
| vs SMA50 | Above (USD 23.21) |
| MACD | 0.75 (positive) |
Analyst Ratings (SMTI)
Wall Street analysts rate SMTI "None" based on 3 analysts, with a mean price target of USD 34.33 (range USD 32–36), per Nexqual as of July 25, 2026 at 17:39 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 34.33 |
| High Target | USD 36 |
| Low Target | USD 32 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (SMTI)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $28.65M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.04 vs est -0.22 ▲ beat |
| 2025-12-31 | USD -0.19 vs est 0.11 ▼ miss |
| 2025-09-30 | USD -3.52 vs est -0.22 ▼ miss |
| 2025-06-30 | USD -0.23 vs est -0.44 ▲ beat |
Source: Nexqual, July 25, 2026 at 17:39 UTC.
Financials & Fundamentals (SMTI)
| Total Revenue | $107.48M |
|---|---|
| Revenue Growth (YoY) | +18.60% |
| Gross Margin | +92.92% |
| Operating Margin | +9.52% |
| Profit Margin | -31.24% |
| ROE | +2.86% |
| Debt / Equity | 689.01 |
| Current Ratio | 2.28 |
| Total Cash | $13.59M |
| Total Debt | $48.37M |
| Free Cash Flow | $5.84M |
Source: Nexqual, July 25, 2026 at 17:39 UTC.
Financial Health Score (SMTI)
Nexqual rates Sanara Medtech Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 17:39 UTC.
| Growth | Strong — Revenue +19% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 93%, operating 10% |
| Balance Sheet | Weak — $14M cash vs $48M debt |
| Cash Flow | Solid — FCF $6M, 6% margin |
| Efficiency | Weak — ROE 3%, ROA 8.3% |
Ownership (SMTI)
| Insider Ownership | +48.10% |
|---|---|
| Institutional Ownership | +16.41% |
| Shares Outstanding | 9.16M |
| Float | 3.74M |
| Short % of Float | +7.10% |
Source: Nexqual, July 25, 2026 at 17:39 UTC.
Leadership (SMTI)
Sanara Medtech Inc. is led by Seth D. Yon (age 50), President, CEO & Director, per Nexqual as of July 25, 2026 at 17:39 UTC.
| President, CEO & Director | Seth D. Yon (age 50) |
|---|---|
| Executive Chairman | Ronald T. Nixon (age 69) |
| Chief Financial Officer | Elizabeth B. Taylor (age 49) |
| Chief Operating Officer | Jacob A. Waldrop (age 43) |
| President & CEO of THP | Suresh V. Muppalla |
Major Backers & Investors (SMTI)
Notable institutional backers of Sanara Medtech Inc. include Royal Bank of Canada, Stonebridge Wealth Management, LLC, Marshall Wace LLP, according to Nexqual as of July 25, 2026 at 17:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Royal Bank of Canada | 2.1% |
| Stonebridge Wealth Management, LLC | 2.07% |
| Marshall Wace LLP | 1.22% |
| Squarepoint Ops LLC | 1.18% |
| Renaissance Technologies | 1.03% |
| Fidelity | 0.79% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.38% |
| Vanguard Group | 5.03% |
| Geode Capital | 1.37% |
| State Street | 1% |
Source: Nexqual, July 25, 2026 at 17:39 UTC.
From Sanara Medtech Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States.
- The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.
- The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TELA | TELA Bio, Inc. | USD 0.69 | ▼ 5.73% |
| HQI | HireQuest, Inc. | USD 12.9 | ▲ 0.86% |
| SIBN | SI-BONE, Inc. | USD 16.62 | ▼ 0.54% |
| PDEX | Pro-Dex, Inc. | USD 54.93 | ▲ 2.81% |
| SPFI | South Plains Financial, Inc. | USD 44.63 | ▲ 1.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 17:39 UTC. This page is informational and not investment advice.